Is Albireo Pharma (NASDAQ:ALBO) losing trust from institutional investors?


USD 19.36  0.63  3.36%   

In general, we focus on analyzing Albireo (NASDAQ:ALBO) price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Albireo Pharma daily price indicators and compare them against related drivers. While some planning is required to successfully invest in stocks, sometimes taking bold action is just as important. Let's try to outline why this may be the case with Albireo Pharma. We will evaluate why recent Albireo Pharma price moves suggest a bounce in September.
Published over a month ago
View all stories for Albireo Pharma | View All Stories
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Albireo Pharma has an asset utilization ratio of 157.44 percent. This suggests that the company is making $1.57 for each dollar of assets. An increasing asset utilization means that Albireo Pharma is more efficient with each dollar of assets it utilizes for everyday operations.
The successful prediction of Albireo Pharma stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Albireo Pharma, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Albireo Pharma based on Albireo Pharma hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Albireo Pharma's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Albireo Pharma's related companies.

Use Technical Analysis to project Albireo expected Price

Albireo Pharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Albireo Pharma technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Albireo Pharma trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...

How does Albireo utilize its cash?

To perform a cash flow analysis of Albireo Pharma, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Albireo Pharma is receiving and how much cash it distributes out in a given period. The Albireo Pharma cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.

Sale by Pamela Stephenson of 445 shares of Albireo Pharma

Legal trades by Albireo Pharma insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Albireo insider trading alert for sale of common stock by Pamela Stephenson, Chief Commercial Officer, on 27th of September 2022. This event was filed by Albireo Pharma Inc with SEC on 2022-09-27. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking down Albireo Pharma Further

The company reported the previous year's revenue of 45.45 M. Net Loss for the year was (32.73 M) with profit before overhead, payroll, taxes, and interest of 39.22 M.
 2019 2020 2021 2022 (projected)
Revenues USD9.64 M8.31 M40.58 M43.78 M
Revenues9.64 M8.31 M40.58 M43.78 M

Cost of Revenue Breakdown

Albireo Pharma Cost of Revenue yearly trend continues to be quite stable with very little volatility. The value of Cost of Revenue is projected to decrease to about 1.2 M. Cost of Revenue usually refers to the aggregate cost of goods produced and sold and services rendered during the reporting period. Albireo Pharma Cost of Revenue is quite stable at the moment as compared to the past year. The company's current value of Cost of Revenue is estimated at 1.21 Million
20101.36 Million
20211.22 Million
20221.21 Million

Our take on today Albireo Pharma rise

Latest maximum drawdown is at 21.01. Albireo Pharma exhibits very low volatility with skewness of -0.36 and kurtosis of 1.72. However, we advise investors to further study Albireo Pharma technical indicators to make sure all market info is available and is reliable. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Albireo Pharma's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Albireo Pharma's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Albireo Pharma Implied Volatility

Albireo Pharma's implied volatility exposes the market's sentiment of Albireo Pharma stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Albireo Pharma's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Albireo Pharma stock will not fluctuate a lot when Albireo Pharma's options are near their expiration.

Our Final Take On Albireo Pharma

Whereas many other companies in the biotechnology industry are either recovering or due for a correction, Albireo may not be as strong as the others in terms of longer-term growth potentials. With an impartial outlook on the current market volatility, it may be better to hold off any inventment activity and neither take in nor exit any shares of Albireo Pharma at this time. The Albireo Pharma risk-reward trade off is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Albireo Pharma.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Albireo Pharma. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to